Mirtazapine Eg (Mirtazapine)

Mirtazapine works by blocking presynaptic α2‑adrenergic receptors, which increases the release of norepinephrine, and by antagonizing 5‑HT2 and 5‑HT3 receptors, enhancing serotonergic activity. It also blocks H1 histamine receptors, contributing to its sedative properties.

The appropriate dose of Mirtazapine Eg is determined by the prescribing healthcare professional based on the individual’s clinical condition, response to therapy, and tolerability. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

Safety data for mirtazapine in pregnancy and lactation are limited. Healthcare providers should weigh the potential benefits against possible risks before prescribing it to pregnant or nursing women. The decision is made on a case‑by‑case basis.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any required import documentation.

Mirtazapine belongs to the NaSSA class, differing from SSRIs and SNRIs by its dual antagonism of α2‑adrenergic and certain serotonin receptors. This mechanism often results in strong sedative and appetite‑stimulating effects, which can be advantageous for patients with insomnia or weight loss, but may be less suitable for those concerned about weight gain.

Mirtazapine Eg should be stored at ambient temperature, below 25 °C, in its original packaging. Keep it away from moisture, direct sunlight, and out of reach of children.

Mirtazapine Eg is taken orally, usually once daily in the evening due to its sedative effect. The tablet should be swallowed whole with water and not crushed or chewed unless otherwise directed by a healthcare professional.

Serious risks include the potential for suicidal thoughts, especially when therapy is initiated or dosage is changed, agranulocytosis, severe hypersensitivity reactions, and serotonin syndrome when combined with other serotonergic drugs. Patients should seek immediate medical attention if any of these occur.

Mirtazapine should be avoided in individuals who have a known hypersensitivity to the drug or any of its excipients, those currently taking monoamine oxidase inhibitors, or patients with uncontrolled severe liver disease. It should also be used with caution in the elderly and in patients with a history of bipolar disorder.